Mereo BioPharma Group PLC Share Price London S.E.
Equities
GB00BZ4G2K23
Biotechnology & Medical Research
Sales 2024 * | 27.5M 34.4M 2.86B | Sales 2025 * | 12.5M 15.64M 1.3B | Capitalization | 308M 385M 32.07B |
---|---|---|---|---|---|
Net income 2024 * | -8M -10.01M -833M | Net income 2025 * | -28M -35.03M -2.92B | EV / Sales 2024 * | 6.53 x |
Net cash position 2024 * | 128M 161M 13.38B | Net cash position 2025 * | 142M 178M 14.8B | EV / Sales 2025 * | 13.3 x |
P/E ratio 2024 * |
-293
x | P/E ratio 2025 * |
-59.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.94% |
Managers | Title | Age | Since |
---|---|---|---|
John P. Richard
FOU | Founder | 66 | 01/15/01 |
Founder | 64 | 10/15/10 | |
Charles Sermon
FOU | Founder | 55 | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 23/19/23 |
Director/Board Member | - | 10/22/10 | |
Director/Board Member | 59 | 23/19/23 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |